Prognostic significance of the p53 mutation in esophageal cancer

Japanese Journal of Clinical Oncology

Volumn 26, Issue 5, 1996, Pages 287-292

  Uchino, Shinya ^a,c   Saito, Takao ^b   Inomata, Masafumi ^a   Osawa, Naofumi ^a   Chikuba, Kiyone ^a   Etoh, Kaoru ^a   Kobayashi, Michio ^a  

^a OITA UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c Hospital Foundation   (Japan)

Author keywords

Human esophageal cancer; p53 gene; PCR SSCP analysis; Prognosis; Tumor suppressor gene

Indexed keywords

ARTICLE; ESOPHAGUS TUMOR; GENETICS; HUMAN; MUTATION; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ESOPHAGEAL NEOPLASMS; GENES, P53; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS;

EID: 0030266901     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.jjco.a023234     Document Type: Article

References (40)

1. Knudson AG Jr: Hereditary cancer, oncogenes, and antioncogenes, Cancer Res 45: 1437-1443, 1985
2. Weinberg RA: Tumor suppressor genes. Science 254: 1138-1146, 1991
3. Sugimura T: Multistep carcinogenesis: a 1992 perspective. Science 258: 603-607, 1992
4. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, vanTuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244: 217-221, 1989
5. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S, Vogelstein B: p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50: 7717-7722, 1990
6. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991
7. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991
9. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA: p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 51: 4495-4499, 1991
10. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, min Zhu SM, Kusters I, Resau JH, Trump BF, Lane DP, Harris CC: p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 52: 6092-6097, 1992
11. Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, Della Porta G, Pierotti MA: Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 52: 6079-6082, 1992
12. Kikuchi-Yanoshita R, Konishi M, Ito S, Seki M, Tanaka K, Maeda Y, lino H, Fukayama M, Koike M, Mori T, Sakuraba H, Fukunari H, Iwama T, Miyaki M: Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res 52: 3965-3971, 1992
13. Uchino S, Noguchi M, Ochiai A, Saito T, Kobayashi M, Hirohashi S: p53 mutation in gastric cancer: a genetic model for carcinogenesis is common to gastric and colorectal cancer. Int J Cancer 54: 759-764, 1993
14. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B: Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-847, 1992
15. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS: Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 84: 845-855, 1992
16. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasaki H, Sugimura T, Terada M: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52: 1393-1398, 1992
17. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi Y, Dohi K, Nakamura N, Akiyama M: Genetic alterations in thyroid tumor progression: association with p53 gene mutations. Jpn J Cancer Res 84: 526-531, 1993
18. Hollstein MC, Smits AM, Galiana C, Yamasaki H, Bos JL, Mandard A, Partensky C, Montesano R: Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res 48: 5119-5123, 1988
19. Lu SH, Hsieh LL, Luo FC, Weinstein IB: Amplification of the EGF receptor and c-myc genes in human esophageal cancers. Int J Cancer 42: 502-505, 1988
20. Sakamoto H, Mori M, Taira M, Yoshida T, Matsukawa S, Shimizu K, Sekiguchi M, Terada M, Sugimura T: Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. Proc Natl Acad Sci USA 83: 3997-4001, 1986
21. Tsutsumi M, Sakamoto H, Yoshida T, Kakizoe T, Koiso K, Sugimura T, Terada M: Coamplification of the hst-1 and int-2 genes in human cancers. Jpn J Cancer Res 79: 428-432, 1988
22. Tsuda T, Tahara E, Kajiyama G, Sakamoto H, Terada M, Sugimura T: High incidence of coamplification of hst-1 and int-2 genes in human esophageal carcinomas. Cancer Res 49: 5505-5508, 1989
23. Kitagawa Y, Ueda M, Ando N, Shinozawa Y, Shimizu N, Abe O: Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma. Cancer Res 51: 1504-1508, 1991
24. Chikuba K, Saito T, Uchino S, Sato K, Miyahara M, Tsuda H, Hirohashi S, Kobayashi M: High amplification of the hst-1 gene correlates with haematogenous recurrence after curative resection of oesophageal carcinoma. Br J Surg 82: 364-367, 1995
25. Meltzer SJ, Yin J, Huang Y, McDaniel TK, Newkirk C, Iseri O, Vogelstein B, Resau JH: Reduction to homozygosity involving p53 in esophageal cancers demonstrated by the polymerase chain reaction. Proc Natl Acad Sci USA 88: 4976-4980, 1991
26. Wagata T, Ishizaki K, Imamura M, Shimada Y, Ikenaga M, Tobe T: Deletion of 17p and amplification of the int-2 gene in esophageal carcinomas. Cancer Res 51: 2113-2117, 1991
27. Japanese Society for Esophageal Diseases: Guide lines for the clinical and pathologic studies on carcinoma of the esophagus. Japanese Journal of Surgery 6: 69-78, 1976
28. Uchino S, Tsuda H, Noguchi M, Yokota J, Terada M, Saito T, Kobayashi M, Sugimura T, Hirohashi S: Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res 52: 3099-3102, 1992
29. Maniatis T, Fritsch EF, Sambrook J: Molecular Cloning: A Laboratory Manual, 2nd ed, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. 1989
30. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86: 2766-2770, 1989
31. Hollstein MC, Peri L, Mandard AM, Welsh JA, Montesano R, Metcalf RA, Bak M, Harris CC: Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res 51: 4102-4106, 1991
32. Wang DY, Xiang YY, Tanaka M, Li XR, Li JL, Shen Q, Sugimura H, Kino I: High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 74: 3089-3096, 1994
33. Tamura G, Maesawa C, Suzuki Y, Satodate R, Ishida K, Saito K: p53 gene mutations in esophageal cancer detected by polymerase chain reaction single-strand conformation polymorphism analysis. Jpn J Cancer Res 83: 559-562,1992
34. Kaketani K, Saito T, Kobayashi M: Flow cytometric analysis of nuclear DNA content in esophageal cancer: aneuploidy as an index for highly malignant potential. Cancer 64: 887-891, 1989
35. el-Deiry WS, Tokino T, Veculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993
36. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993
37. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993
38. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90-98, 1994
39. Tsuruta H, Sakamoto H, Onda M, Terada M: Amplification and overexpression of EXP1 and EXP2/Cyclin D1 genes in human esophageal carcinomas. Biochem Biophys Res Commun 196: 1529-1536, 1993
40. Sherr CJ: Mammalian G1 cyclins. Cell 73: 1059-1065, 1993